Management of biochemical failure following radical prostatectomy: Salvage radiotherapy - A case series

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 2, 2007, Pages 205-209

  Stockdale, A D ^a   Vakkalanka, B K ^a   Fahmy, A ^a   Desai, K ^a   Blacklock, A R E ^a  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CASE STUDY; CLINICAL OBSERVATION; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PATIENT SELECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIATION DOSE; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SEMINAL VESICLE; THERAPY EFFECT; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 34250000507     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500943     Document Type: Article

References (24)

1. Cancer stats; Incidence-UK. www.cancerresearch.org. September 2002.
2. Oliver SE, Donovan JL, Peters TJ, Frankel S, Hamdy FC, Neal DE. Recent trends in the use of radical prostatectomy in England: The epidemiology of diffusion. BJU Int 2003; 91: 331-336.
3. British Association of Urological Surgeons. Section of Oncology. Cancer Registry 2005.
4. Catalona WJ, Smith DS. 5-year tumour recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-1842.
5. Kupelian PA, Katcher J, Levin HS, Klein EA. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043-1052.
6. Winkler MH, Khan FA, Hoh IM, Okeke AA, Sugiono M, McInerney P et al. Time trends in case selection, stage and prostate specific antigen recurrence after radical prostatectomy: A multicentre audit. BJU Int 2004; 93: 725-729.
7. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-1597.
8. Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J et al. Late effects toxicity scoring: The SOMA scale. Radiother Oncol 1995; 35: 11-15.
9. Wieder JA, Soloway MS. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 1998; 160: 299-315.
10. Shekarriz B, Upadhyay J, Wood Jr DP, Hinman J, Raasch J, Cummings GD et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate specific antigen and pathologic stage. Urology 1999; 54: 1044-1048.
11. Koppie TM, Grossfeld GD, Nudell DM, Weinberg VK, Carroll PR. Is anastomotic biopsy necessary before radiotherapy after radical prostatectomy? J Urol 2001; 166: 111-115.
12. Cher ML, Bianco Jr FJ, Lam JS, Davis LP, Grignon DJ, Sakr WA et al. Limited role of bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 1998; 160: 1387-1391.
13. Kramer S, Gorich J, Gottfried HW, Riska P, Aschoff AJ, Rilinger N et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol 1997; 70: 995-999.
14. Lange PH, Lightner DJ, Medini E, Reddy PK, Vessella RL. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 1990; 144: 927-933.
15. Caddedu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998; 159: 173-178.
16. Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004; 291: 1325-1332.
17. Consensus statements on radiation therapy of prostate cancer. Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 1999; 17: 1155-1163.
18. Connolly JA, Shinohara K, Presti Jr JC, Carroll PR. Local recurrence after radical prostatectomy. Characteristics in size, location and relationship to prostate-specific antigen and surgical margins. Urology 1996; 47: 225-231.
19. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 2003; 56: 755-763.
20. Syndikus I, Pickles T, Kostashuk E, Sullivan LD. Post operative radiotherapy for stage pT3 carcinoma of the prostate: Improved local control. J Urol 1996; 155: 1983-1986.
21. Morris SL, Parker C, Huddart R, Horwich A, Dearnaley D. Current opinion on adjuvant and salvage treatment after radical prostatectomy. Clin Oncol 2004; 16: 277-282.
22. Lee LW, McBain CA, Swindell R, Wylie JP, Cowan RA, Logue JP. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy. Clin Oncol 2004; 16: 517-522.
23. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? J Urol 2001; 165: 1146-1151.
24. Bolla M, van Poppel H, Collette L, Voncangh P, Vekemans K, DaPozzo L et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578.